A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality
<i>Introduction</i>: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive mod...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/4/675 |
| _version_ | 1797604450158772224 |
|---|---|
| author | Zuleyha Akgun Aydin Cakir Esra Sağlam Sertac Demirel Abdullah Igci Serkan Keskin |
| author_facet | Zuleyha Akgun Aydin Cakir Esra Sağlam Sertac Demirel Abdullah Igci Serkan Keskin |
| author_sort | Zuleyha Akgun |
| collection | DOAJ |
| description | <i>Introduction</i>: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), or a hybrid therapy approach. <i>Material/Methods</i>: This investigation involved administering hypofractionated SIB-VMAT therapy to individuals diagnosed with early-stage breast cancer. Treatment was carried out over a three-week period in which a total dose of 48.06 Gy was given to the entire breast and 54 Gy was given to the tumor bed. Data on skin toxicity and cosmetic outcomes were analyzed both during the acute phase and during the three-month and five-year follow-up periods after treatment. <i>Results</i>: A total of 125 patients treated between December 2014 and December 2016 were included in the study. The data of these patients with at least 5 years of follow-up were analyzed. <i>Conclusions</i>: Considering these long-term results, hypofractionated SIB-VMAT can be considered a viable treatment choice, even for patients with unfavorable conditions. |
| first_indexed | 2024-03-11T04:46:19Z |
| format | Article |
| id | doaj.art-4f6ffaa9803c44228fdea5e2adcbb854 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-11T04:46:19Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-4f6ffaa9803c44228fdea5e2adcbb8542023-11-17T20:20:21ZengMDPI AGMedicina1010-660X1648-91442023-03-0159467510.3390/medicina59040675A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health QualityZuleyha Akgun0Aydin Cakir1Esra Sağlam2Sertac Demirel3Abdullah Igci4Serkan Keskin5Department of Radiation Oncology, Memorial Sisli Hospital, Kaptan Paşa, Kaptan Paşa Mahallesi, Piyale Paşa Bulvari, Istanbul 34384, TurkeyDepartment of Radiation Oncology, Memorial Sisli Hospital, Kaptan Paşa, Kaptan Paşa Mahallesi, Piyale Paşa Bulvari, Istanbul 34384, TurkeyDepartment of Radiation Oncology, Memorial Sisli Hospital, Kaptan Paşa, Kaptan Paşa Mahallesi, Piyale Paşa Bulvari, Istanbul 34384, TurkeyDepartment of General Surgery, Memorial Sisli Hospital, Kaptan Paşa, Kaptan Paşa Mahallesi, Piyale Paşa Bulvari, Istanbul 34384, TurkeySchool of Medicine, Department of General Surgery, Istanbul University, Istanbul 34452, TurkeyDepartment of Medical Oncology, Memorial Sisli Hospital, Kaptan Paşa, Kaptan Paşa Mahallesi, Piyale Paşa Bulvari, Istanbul 34384, Turkey<i>Introduction</i>: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), or a hybrid therapy approach. <i>Material/Methods</i>: This investigation involved administering hypofractionated SIB-VMAT therapy to individuals diagnosed with early-stage breast cancer. Treatment was carried out over a three-week period in which a total dose of 48.06 Gy was given to the entire breast and 54 Gy was given to the tumor bed. Data on skin toxicity and cosmetic outcomes were analyzed both during the acute phase and during the three-month and five-year follow-up periods after treatment. <i>Results</i>: A total of 125 patients treated between December 2014 and December 2016 were included in the study. The data of these patients with at least 5 years of follow-up were analyzed. <i>Conclusions</i>: Considering these long-term results, hypofractionated SIB-VMAT can be considered a viable treatment choice, even for patients with unfavorable conditions.https://www.mdpi.com/1648-9144/59/4/675breast cancerSIBhypofractionationhybrid radiotherapylate toxicity |
| spellingShingle | Zuleyha Akgun Aydin Cakir Esra Sağlam Sertac Demirel Abdullah Igci Serkan Keskin A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality Medicina breast cancer SIB hypofractionation hybrid radiotherapy late toxicity |
| title | A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality |
| title_full | A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality |
| title_fullStr | A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality |
| title_full_unstemmed | A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality |
| title_short | A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality |
| title_sort | hypofractionated radiotherapy schedule with a simultaneous integrated boost for breast cancer outcomes including late toxicity and health quality |
| topic | breast cancer SIB hypofractionation hybrid radiotherapy late toxicity |
| url | https://www.mdpi.com/1648-9144/59/4/675 |
| work_keys_str_mv | AT zuleyhaakgun ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT aydincakir ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT esrasaglam ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT sertacdemirel ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT abdullahigci ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT serkankeskin ahypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT zuleyhaakgun hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT aydincakir hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT esrasaglam hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT sertacdemirel hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT abdullahigci hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality AT serkankeskin hypofractionatedradiotherapyschedulewithasimultaneousintegratedboostforbreastcanceroutcomesincludinglatetoxicityandhealthquality |